NEW YORK, Jan. 29 Reportlinker.com announces that a new market research report is available in its catalogue:
Anti-Obesity Drugs - Trends & Opportunities Worldwide
Advertisement
http://www.reportlinker.com/p0164264/Anti-Obesity-Drugs---Trends--Opportunities-Worldwide.html
The world today is facing an acute crisis of over-weightiness and its more advance form, obesity. The need to combat obesity may be understood from the fact that it gives rise to life threatening ailments such as heart attack, hypertension, diabetes and certain types of cancer. Obesity prevalence translates to wider opportunities for drug companies, as there exists a huge market for highly efficacious and novel anti-obesity drugs. As such, major proportion of currently available drugs does not meet existing requirements for safety profile and efficacy.
Advertisement
These and other market data and trends are presented in "Anti-Obesity Drugs: Trends & Opportunities Worldwide" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
ANTI-OBESITY DRUGS BMR-1064
CONTENTS
1. METHODOLOGY 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Quantitative Techniques & Reporting Level 3
2. GLOBAL MARKET OVERVIEW AND OUTLOOK 4
Factors Influencing the Market 4
Obesity - A Global Epidemic 4
Trends and Issues 7
Obesity: An Unmet Medical Need 7
Rising Demand for Obesity Therapeutics 7
Barriers to Development of Effective Drugs 7
New Research Aids in Discovery of Novel Drugs 8
Growing Problem of Obesity in Asia Particularly China 8
3. COMPETITION 9
Roche Leads the Race 9
Competition Grows with Pipeline Drugs 10
Current Anti-Obesity Drugs in Pipeline: 2008 11
4. PRODUCT FACTS 11
Diagnosis of Obesity 11
BMI Classification 11
Waist Circumference and BMI 12
Causes of Obesity 12
Select causes of obesity 12
Risks Associated with Obesity 12
Obesity Treatment 13
Review of Available Drugs 14
Phentermine 14
Sibutramine 14
Orlistat 14
Anti-obesity Drugs, Brands and Mechanism of Action 14
5. CORPORATE DEVELOPMENTS 15
Pfizer Halts CP-945, 598 Development 15
Shionogi to Acquire Sciele Pharma 15
Anthill Inks Agreement with Zafgen 15
EMEA Suspends Acomplia 15
GlaxoSmithKline to Sell Alli as OTC Drug 16
Sanofi-Aventis to Market Acomplia in UK 16
Orexigen Receives 4th US Patent for Contrave 16
BELLUS Health to Acquire Innodia 16
Ore Secures License to Develop Romazarit 16
GlaxoSmithKline Receives FDA Approval for Orlistat 17
Pfizer Receives Approval for Slentrol 17
GlaxoSmithKline Secures Licensing Rights of Orlistat 17
Pfizer Collaborates with Bristol-Myers Squibb 17
Takeda Collaborates with LG Life Sciences 18
Takeda to Acquire Paradigm 18
Sanofi-Aventis Secures Reimbursement Status for Acomplia 18
AstraZeneca Inks Agreement with Palatin Technologies 19
Switzerland Includes Acomplia in Reimbursement List 19
Allergan Pockets EndoArt 19
Sanofi-Aventis Receives Approval for Acomplia in Brazil 20
Biocon Inks MoU with Neopharma 20
Aurigene Partners with Forest Laboratories 20
Sanofi-Aventis Receives Swiss Approval for Acomplia 20
Zydus Cadila Introduces Slimona 21
Torrent Introduces Rimoslim 21
Genaera Initiates First Human Trial of Trodusquemine 21
Neurogen Completes First Trial of NGD-4715 21
Alizyme Secures USFDA Approval for Cetilistat Trials 21
GW Pharma to Start Human Trials of New Anti Obesity Drug 22
Epix Completes Phase Ib Trial of PRX-07034 22
7TM Pharma Starts Phase I/II Trial of TM30339 22
6. MAJOR PLAYERS 22
Abbott Laboratories (US) 22
Alizyme Plc (UK) 22
Amylin Pharmaceuticals, Inc. (US) 23
AstraZeneca Plc (UK) 23
F. HOFFMANN-LA ROCHE LTD. (Switzerland) 23
GlaxoSmithKline Plc (UK) 24
Sanofi-Aventis SA (France) 24
SuperGen, Inc. (USA) 24
Takeda Pharmaceutical Company Limited (Japan) 24
VIVUS, Inc. (US) 25
7. GLOBAL MARKET ANALYTICS 25
8. THE UNITED STATES 26
Market Overview 26
Obesity Catching Them Young 27
New Drugs to Rule the Market 27
37 States Experience Increase in Adult Obesity Rate 27
Statistical Data 28
Reimbursement Scenario 29
Regulatory Environment 29
Insufficient Regulatory and Enforcement Laws 30
Obesity and Related Ailments: Burden on Societal and Economic
Cost 30
Competition 30
9. EUROPE 31
a. France 35
b. Germany 36
c. Italy 37
d. The United Kingdom 37
e. Rest of Europe 38
10. REST OF WORLD 39
Brief Review of Select Regions 39
Canada 39
Asia-Pacific 39
Australia 39
China 40
India 40
Drugs Under Development by Indian Companies 41
Japan 41
Korea 41
Use of Diet Pills Lack Proper Monitoring 41
New Zealand 42
EXHIBITS
Table 1: Global Overweight Prevalence (2006): Overweight
Population (%) of Select Countries (BMI ³ 25)
Table 2: Abdominal Obesity Prevalence (%) by Region and Sex
Table 3: Percentage Share Breakdown of Leading Anti-obesity
Drugs Brand Revenues in the World - 2007
Table 4: Obesity Treatment Options and Corresponding Success
Rate
Table 5: Percentage Share Breakdown of Anti-obesity
Prescription Drugs Market by Physician Practices in the
World - 2006
Table 6: Global Anti-Obesity Drugs Market by Region for the
Period 2007-2015 (Sales in US$ Million)
Table 7: Percentage Breakdown of Global Anti-Obesity Drugs
Market by Region for the Years 2009 & 2012
Table 8: Percent Share Breakdown of Leading Weight Loss
Manufacturer Revenues in the US - 2008E
Table 9: US Obesity Rate (2007): Prevalence Rate of Leading
States
Table 10: US Obesity Prevalence Estimates and Forecast
(2008-2020)
Table 11: Percentage Share Breakdown of Anti-obesity
Prescription Drugs Brand Revenues - 2007
Table 12: Anti-Obesity Drugs Market by Segment in the US:
2007-2015 (Sales in US$ Million)
Table 13: Obesity Prevalence (2007) in Select European Union
Countries: Obesity Rates by Gender
Table 14: Europe Obesity Prevalence (2007) by Gender and Age
Category (in 000s)
Table 15: Anti-Obesity Drugs Market by Region in Europe:
2007-2015 (Sales in US$ Million)
Table 16: Percentage Breakdown of Anti-Obesity Drugs Market by
Region in Europe for the Years 2009 & 2012
Table 17: Anti-Obesity Drugs Market by Segment in France:
2007-2015 (Sales in US$ Million)
Table 18: Percentage Share Breakdown of Leading Anti-obesity
Drugs Brand Volume Sales in Germany - 2006
Table 19: Anti-Obesity Drugs Market by Segment in Germany:
2007-2015 (Sales in US$ Million)
Table 20: Anti-Obesity Drugs Market by Segment in Italy:
2007-2015 (Sales in US$ Million)
Table 21: Anti-Obesity Drugs Market by Segment in UK:
2007-2015 (Sales in US$ Million)
Table 22: Anti-Obesity Drugs Market by Segment in Rest of
Europe: 2007-2015 (Sales in US$ Million)
Table 23: Prevalence Rate (%) of Overweight/ Obese Students in
Australia
Table 24: Anti-Obesity Drugs Market by Segment in Rest of
World: 2007-2015 (Sales in US$ Million)
COMPANIES PROFILED
To order this report:
Pharmaceutical Industry: Anti-Obesity Drugs - Trends & Opportunities Worldwide
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg Reportlinker Email: [email protected] US: (805)652-2626 Intl: +1 805-652-2626
SOURCE Reportlinker
